Helsinn Healthcare S.A. v. Cipla Ltd. et al.

I'll research this case thoroughly before writing the overview.

Good foundation. Now let me verify the consolidation, the outcome, and the appellate/IPR history — including why the '725 patent matters.

Now let me pin down what happened in the Delaware consolidated case, Cipla's ANDA, and any IPR activity on the '725 patent.

Case Overview: Helsinn Healthcare S.A. v. Cipla Ltd., No. 1:14-cv-00427-GMS (D. Del.)

The parties and the product. Helsinn Healthcare S.A. is a privately held Swiss pharmaceutical company based in Lugano that developed and owns ALOXI® (palonosetron hydrochloride) injection, a second‑generation 5‑HT₃ receptor antagonist approved in July 2003 (NDA No. 021372) for chemotherapy‑induced nausea and vomiting (CINV); it is the only 5‑HT₃ antagonist FDA‑approved for delayed CINV, and Helsinn's U.S. marketing partner is Eisai. Helsinn is an operating innovator company, not an NPE/PAE — this is conventional Hatch‑Waxman ANDA litigation. Helsinn's co‑plaintiff, Roche Palo Alto LLC, appears in the case because Roche/Syntex discovered palonosetron and licensed it (and the underlying U.S. Patent No. 5,202,333) to Helsinn in 1998; Roche's Rule 7.1 disclosure identified Roche Holdings and Novartis affiliates (CourtListener docket, D.I. 9). The defendants are Cipla Ltd., the Mumbai‑based Indian generics manufacturer, and its U.S. distribution arm Cipla USA, Inc. (parent: Cipla (Mauritius) Limited per D.I. 11–12).

What is accused. Cipla's ANDA No. 206396, a Paragraph IV filing seeking approval to market a generic 0.25 mg/5 mL palonosetron hydrochloride intravenous solution — a copy of ALOXI® — before expiration of Helsinn's Orange Book patents, with a § 505(j)(2)(A)(vii)(IV) certification of invalidity/non‑infringement. Helsinn pleaded infringement under 35 U.S.C. § 271(e)(2)(A) and sought a declaration plus an order under § 271(e)(4)(A) delaying ANDA approval (complaint text as reproduced in the RPX litigation document). Helsinn gave notice of the certification on February 25, 2014, and the docket records a thirty‑month stay deadline of August 25, 2016 (docket entry of Apr. 8, 2014).

The patents. The case is one piece of a multi‑patent, multi‑defendant campaign over the same "Liquid Pharmaceutical Formulations of Palonosetron" family, all claiming priority to a January 30, 2003 provisional. Per the case metadata the operative patent is U.S. 7,947,725 — claim 2 (the claim the Federal Circuit treated as representative) recites a pharmaceutically stable solution of 0.05 mg/mL palonosetron HCl in sterile injectable aqueous carrier at pH 4.5–5.5, 0.005–1.0 mg/mL EDTA, and mannitol tonicifier at ~10–80 mg/mL. In one line each, the family members: the '725 claims the low‑concentration buffered/EDTA/mannitol IV formulation; the '724 and '424 claim closely related pre‑AIA formulation variants; the '981 claims related liquid formulations; the '218 and '219 (both issued Dec. 3, 2013) claim liquid palonosetron formulations, with the post‑AIA '219 claiming a single‑use 0.25 mg/5 mL unit dose stable 24 months at room temperature; and the '094 (issued May 20, 2014) is the later‑issuing sibling added by stipulation (D.I. 19 in 14‑427 / D.I. 56 in 13‑688, June 17, 2014). Docket practice in the case was messy: the complaint and the plaintiffs' patent report listed the '218 and '219, while Cipla's counterclaim patent report listed the '724, '725, '424, and '981 (docket entries Apr. 29, 2014), and the '725 was the family's center of gravity throughout the Aloxi litigation. All of these patents carried an Orange Book expiry of July 30, 2024 including pediatric exclusivity (FDA approval letter, ANDA 090713).

Posture, venue, and why it matters. Filed April 7, 2014 in the District of Delaware and assigned to Chief Judge Gregory M. Sleet (Courtroom 4A, Wilmington), the case was consolidated for all purposes on July 10, 2014 into lead case No. 1:13‑cv‑00688‑GMS alongside Helsinn's suits against Aurobindo/AuroMedics (13‑688), Ben Venue/Bedford (13‑1612), and Accord (13‑2101), under a single scheduling order (Markman Feb. 18, 2015; fact discovery to Mar. 11, 2015; five‑day jury trial set for Nov. 2, 2015) (D.I. 19, July 10, 2014). Delaware was the natural forum: every major ANDA filer was already there or in D.N.J., the court had an assembled palonosetron MDL‑style consolidation, and Judge Sleet's patent docket gave Helsinn scheduling leverage over roughly fifteen ANDA sponsors. The Delaware case never reached a merits ruling — the docket shows the case closed on October 27, 2015 (minute entry "CASE CLOSED"; D.I. 25 report to the Patent Office), consistent with the settlement wave in which Helsinn settled with Sandoz (January 2015, generic entry Sept. 30, 2018 or earlier under certain circumstances, Helsinn press release) and Dr. Reddy's (October 2015). Its notability is derivative but significant: the invalidity theory that defeated the '725 was litigated by Teva in the parallel D.N.J. action, Helsinn Healthcare v. Teva (No. 2:11‑cv‑03962, Judge Mary L. Cooper), where Helsinn won a bench trial in June 2015 and a November 16, 2015 judgment of validity/infringement; the Federal Circuit reversed on May 1, 2017, holding the April 2001 Helsinn–MGI license and supply agreement was an invalidating sale under both pre‑AIA § 102(b) and AIA § 102(a)(1) and that the invention was ready for patenting (855 F.3d 1356). The Supreme Court affirmed unanimously on January 22, 2019, holding that an inventor's sale to a party obliged to keep the invention confidential can still trigger the AIA on‑sale bar (586 U.S. 731; 139 S. Ct. 628) — the leading AIA on‑sale‑bar precedent, arising directly out of the '725 patent's claim 2. Commercially, the invalidation opened the floodgates: Teva launched generic ALOXI® at risk on March 23, 2018, Dr. Reddy's on March 26, 2018, and Sandoz on April 2, 2018, all before the Sept. 30, 2018 settlement date (as recited in Helsinn's own briefing in Helsinn v. Sagent, D.N.J. No. 2:16‑cv‑00173, D.I. 53/71). PTAB activity in the family was against siblings rather than the '725 — Accord's PGR on the '219 (filed Sept. 2, 2014), Dr. Reddy's IPR on the '094 (filed July 3, 2015), and Dr. Reddy's PGR on the '942 — so the '725's fate was decided in district court and on appeal, not at the Board.

Sourcing caveats. (1) I could not pull the actual Delaware dismissal/settlement papers or a consent judgment in No. 14‑427 from PACER in this session; the October 27, 2015 closure is documented on the CourtListener docket, but the instrument of dismissal and any settlement terms are not verified here (Helsinn's settlements have been confidential). (2) Public reporting is inconsistent about which patents were formally in suit against Cipla at each stage; I have described the pleaded record (complaint: '218/'219; counterclaim report: '724/'725/'424/'981; amended pleadings adding the '094) and relied on the case metadata for the '725 as the operative patent. (3) I found no IPR petition against the '725 itself; that absence reflects my searches and is not a definitive negative. (4) Aloxi sales figures are cited in Helsinn's PTAB filings as exceeding $3.6 billion in cumulative U.S. sales (Patent Owner's Preliminary Response, PGR2016‑00007); I did not independently verify annual revenue.

I'll research this case across dockets, opinions, and PTAB records.

Helsinn Healthcare S.A. v. Cipla Ltd., No. 1:14-cv-00427-GMS (D. Del.)

Important framing note before the chronology. The case metadata lists only the '725 patent, but the '725 patent was not the patent Helsinn asserted against Cipla. The 14-427 complaint asserted U.S. Pat. Nos. 8,598,218 and 8,598,219 (both issued 2013-12-03; "Liquid Pharmaceutical Formulations of Palonosetron"). After consolidation, Helsinn's operative assertion against Cipla was the '219 and '094 patents — Plaintiffs' own Dec. 5, 2014 claim construction brief states: "Plaintiffs assert [the '724, '725, '424, '219 and '094 patents] against Mylan, and the '219 and '094 patents against Cipla." The '725 (and '724, '424, '851, '218) appear in the case inventory only because of Cipla's counterclaim/Patent Office reporting forms and the multi-defendant consolidated lead case. I flag this because any summary that says Helsinn tried the '725 patent against Cipla would be inaccurate.

---

1. Filing and initial pleadings

2. Consolidation and the amended pleadings (the real "case management" event)

• 2014-05-20: telephonic status conference before Judge Sleet; the four Delaware ANDA actions (13-688, 13-1612, 13-2101, 14-427) were being coordinated.
• 2014-06-03 and 2014-06-11: stipulated extensions of the deadline to submit a consolidation proposal (D.I. 17, 18 in 14-427).
• 2014-07-01: Order consolidating 13-688, 13-1612, 13-2101 and 14-427 for all purposes, designating 13-688 as the lead case; all future filings to be made only in 13-688. The order also set the schedule: claim construction opening briefs 2014-10-14, answering 2014-11-21, 3-hour Markman hearing 2015-02-18, fact discovery close 2015-03-11, expert reports 4/17, 5/29 and 6/26/2015, pretrial order 2015-09-09, final pretrial conference 2015-09-29, 5-day jury trial 2015-11-02 (later described in the docket as

I'll research the docket and related sources for plaintiff's counsel in this case.

Good initial hits. Now let me pull the docket details and verify counsel backgrounds.

Let me examine the docket entries and confirm pro hac vice admissions.

Bottom line

Two firms signed the complaint as counsel of record for the plaintiffs: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, Delaware) as Delaware/local counsel of record, and Paul Hastings LLP (New York) as Helsinn's national "of counsel" team. A third firm, Loeb & Loeb LLP (New York), appeared for the co-plaintiff Roche Palo Alto LLC. Note one discrepancy with the case metadata: the docket caption is Helsinn Healthcare S.A. et al. v. Cipla Ltd. et al. and Roche Palo Alto LLC appears as a co-plaintiff on the pleadings, even though the metadata lists Helsinn alone (see caveats below).

Counsel of record for the plaintiff(s)

Sourcing

• D.I. 1 (Complaint, filed 4/7/2014), signature block — Morris Nichols (Blumenfeld, Noreika) "Attorneys for Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC"; "OF COUNSEL" Paul Hastings (O'Malley, Wexler, Dittmann, Conca, Ji, Ni) "Attorneys for Plaintiff Helsinn Healthcare S.A."; Loeb & Loeb (Waddell) "Attorneys for Plaintiff Roche Palo Alto LLC." Reproduced at https://patentdocs.typepad.com/files/helsinn-v-cipla.pdf (Case 1:14-cv-00427-GMS, Doc. 1, p. 8).
• CourtListener parties page, Helsinn Healthcare S.A. v. Cipla Ltd., 1:14-cv-00427 — lists Helsinn as counter-defendant represented by Jack B. Blumenfeld and Maryellen Noreika (Morris Nichols): https://www.courtlistener.com/docket/13252227/parties/helsinn-healthcare-sa-v-cipla-ltd/
• Stipulation and Order, June 2014 (C.A. No. 13-688-GMS consolidated, including C.A. No. 14-427-GMS) repeating the same Paul Hastings / Loeb & Loeb / Morris Nichols designations: https://storage.courtlistener.com/recap/gov.uscourts.ded.53201.27.0.pdf
• Claim construction briefing in the consolidated Delaware palonosetron actions (D.I. 119, 12/05/2014) filed by the same Paul Hastings team for Helsinn/Roche: https://storage.courtlistener.com/recap/gov.uscourts.ded.51743.119.0.pdf
• Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) (counsel listing naming O'Malley and Dittmann); Supreme Court merits-stage coverage identifying O'Malley as Helsinn co-counsel (Law.com, June 25, 2018).

Defendant-side counsel (for completeness / docket hygiene)

Cipla was represented in Delaware by John C. Phillips, Jr., Megan C. Haney, and David A. Bilson (Phillips Goldman & Spence, P.A. / Phillips, Goldman, McLaughlin & Hall, P.A., Wilmington), with Robert F. Green, Caryn C. Borg-Breen, John P. Snow, and (later) Jessica M. Tyrus of Leydig, Voit & Mayer, Ltd. (Chicago) admitted pro hac vice (D.I. 14 and subsequent PHV orders). The CourtListener docket confirms these PHV motions and orders.

Caveats and unverified points

1. Pro hac vice orders for the Paul Hastings team were not located. I could confirm PHV motions/orders only for Cipla's Leydig Voit attorneys in this docket (D.I. 14, granted 5/16/2014). The Paul Hastings lawyers appear in the record as "OF COUNSEL" on pleadings signed by Morris Nichols, which is standard D. Del. practice, but I did not retrieve the specific PHV motions/orders admitting O'Malley, Wexler, Dittmann, Conca, Ji, or Ni in 14-427. Treat their formal admission status as unconfirmed.
2. Party/patent mismatch with the metadata. The metadata lists Helsinn alone and the '725 patent only. The actual pleadings and docket show (a) Roche Palo Alto LLC as a co-plaintiff, and (b) the April 7, 2014 complaint asserted only the '218 and '219 patents; Cipla's April 29, 2014 answer/counterclaims referenced a broader palonosetron family ('724, '725, '424, '981, '218, '219), and third-party litigation trackers (DrugPatentWatch) list all six patents for this docket. The '725 patent's appearance in this case therefore most likely runs through the counterclaims/amended pleadings rather than the original complaint — I could not pull the specific amended complaint before running out of search steps.
3. No in-house counsel identified. I found no Helsinn corporate/inside counsel on the docket; Helsinn (Lugano/Pambio-Norano, Switzerland) appears to have litigated exclusively through outside counsel.
4. Termination. The docket shows termination on 10/27/2015, consistent with settlement, but I did not retrieve the specific dismissal stipulation/order (e.g., a Rule 41(a) stipulation) or any license/settlement terms — those are not public.
5. The "TERMINATED: 08/01/2018" notation for Noreika on the CourtListener parties page post-dates the case's 2015 termination, which is anomalous; it likely reflects a withdrawal in a related/consolidated palonosetron matter or a CourtListener docket-aggregation artifact rather than an event in 14-427 itself. I did not verify the underlying entry.
6. Firm/affiliation currency. Firm names reflect the 2014–2015 record (Phillips Goldman & Spence later became Phillips, Goldman, McLaughlin & Hall; Paul Hastings and Loeb & Loeb are unchanged). I did not verify each attorney's current practice.

I'll research the docket and counsel appearances for this case.

Good initial hits. Let me verify the docket entries and pro hac vice orders, and check a later filing that lists different local counsel.

Counsel of Record — Defendants Cipla Ltd. and Cipla USA, Inc.

Helsinn Healthcare S.A. v. Cipla Ltd., No. 1:14-cv-00427-GMS (D. Del.)

A threshold point on scope: on July 10, 2014, Judge Sleet consolidated this case with 1:13-cv-00688-GMS, 1:13-cv-01612-GMS, and 1:13-cv-02101-GMS "for all purposes," designating 13-cv-688 as the lead case, with all future filings to be made only there. (D.I. 19 minute entry / order, 7/10/2014) So the Cipla appearances below were made on this docket, but subsequent substantive filings were captioned in 13-cv-688.

Delaware local counsel — Phillips, Goldman & Spence, P.A. (now Phillips, Goldman, McLaughlin & Hall, P.A.)

1200 North Broom Street, Wilmington, DE 19806 · (302) 655-4200

(Source: Cipla's Answer, Affirmative Defenses and Counterclaim, filed Apr. 29, 2014 by John C. Phillips, Jr.; D.I. 10 service list dated July 11, 2014, reproduced at insight.rpxcorp.com/litigation_documents/10828014; CourtListener party page.)

Lead / trial counsel (of counsel, admitted pro hac vice) — Leydig, Voit & Mayer, Ltd.

Two Prudential Plaza, Suite 4900, 180 North Stetson, Chicago, IL 60601-6731

(Sources: D.I. 10 service list (7/11/2014); D.I. 14 PHV motion and "SO ORDERED" endorsement, May 16, 2014; D.I. 24 and the Aug. 5, 2014 deficiency notice on the CourtListener docket.)

Items I want to flag rather than assert

• No in-house Cipla attorney appears of record on the public docket for this case. If Cipla in-house counsel participated, they did not enter an appearance — I found no entry for one.
• Do not confuse with later Cipla counsel. A Delaware filing in the Helsinn palonosetron family signed by Kelly E. Farnan (Richards, Layton & Finger) as "[a]ttorneys for Defendants Cipla Ltd. and Cipla USA, Inc." appears in a different CourtListener docket (recap ID ded.78111), i.e., one of the related/later palonosetron matters — not verified as a filing in 14-cv-427. Same caution for the Cozen O'Connor (Sunshine/Schaubert) Cipla appearances, which come from a D.N.J. palonosetron case. If you need the post-2015 Cipla Delaware lineup (relevant to the 2018 Helsinn v. Cipla litigation), that has to be pulled from the later docket, not this one.
• Firm-name drift. CourtListener renders the Delaware firm in its current form, "Phillips, Goldman, McLaughlin & Hall, P.A."; contemporaneous 2014 filings say "Phillips Goldman & Spence, P.A." Same firm, renamed. Separately, Green and Borg-Breen are widely reported to have later moved to their own Chicago boutique; I did not independently verify that in this research, so I'm not stating it as docket fact.
• Settlement. The case was terminated October 27, 2015; the docket shows no trial (the 11/2/2015 jury trial setting was vacated by the resolution). Counsel's withdrawal/dismissal-stipulation filings at the close of the case are the best place to confirm who was still of record at termination — I could not retrieve the final dismissal papers to verify whether any of the above had withdrawn earlier.

Bottom line: Cipla was represented by a two-tier team — John C. Phillips, Jr. (with Megan C. Haney and David A. Bilson) of Phillips Goldman in Wilmington as Delaware counsel of record, and Robert F. Green, Caryn C. Borg-Breen, and John P. Snow of Leydig, Voit & Mayer in Chicago as PHV lead/of-counsel, with Jessica M. Tyrus's PHV admission unresolved on the public record.